Redeye ups its near-term sales estimates and adjusts its fair value range for Acarix following steps forward on the US market and the recent capital injection. The partnership with the American College of Cardiology could prove to be an important piece of the puzzle, and we see eventful times in 2023 and 2024 for Acarix.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Acarix - Gearing Up

© Modular Finance, source Nordic Press Releases